Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) saw a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 50,692 shares, a decrease of 12.7% from the January 15th total of 58,049 shares. Based on an average daily volume of 70,257 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.6% of the company’s stock are short sold. Approximately 0.6% of the company’s stock are short sold. Based on an average daily volume of 70,257 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned 0.12% of Anebulo Pharmaceuticals as of its most recent filing with the SEC. 28.40% of the stock is currently owned by institutional investors.

Anebulo Pharmaceuticals Trading Up 0.9%

Anebulo Pharmaceuticals stock opened at $0.48 on Tuesday. Anebulo Pharmaceuticals has a 1-year low of $0.44 and a 1-year high of $3.42. The firm has a market capitalization of $19.53 million, a price-to-earnings ratio of -2.52 and a beta of -0.81. The firm’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $2.02.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings results on Friday, February 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. On average, research analysts forecast that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.